HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jeffrey Forrester Selected Research

CUDC 305

12/2009Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
6/2009CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jeffrey Forrester Research Topics

Disease

4Neoplasms (Cancer)
05/2010 - 06/2009
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2009 - 06/2009
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/2009
1Colorectal Neoplasms (Colorectal Cancer)
06/2009
1Breast Neoplasms (Breast Cancer)
06/2009
1Pathologic Processes
06/2006

Drug/Important Bio-Agent (IBA)

2Phosphotransferases (Kinase)IBA
05/2010 - 12/2009
27- (4- (3- ethynylphenylamino)- 7- methoxyquinazolin- 6- yloxy)- N- hydroxyheptanamideIBA
05/2010 - 03/2010
2ErbB Receptors (EGF Receptor)IBA
05/2010 - 12/2009
2Pharmaceutical PreparationsIBA
05/2010 - 06/2009
2CUDC 305IBA
12/2009 - 06/2009
2Erlotinib Hydrochloride (CP 358,774)FDA Link
12/2009 - 06/2009
1human ERBB2 proteinIBA
05/2010
1Histone Deacetylases (Histone Deacetylase)IBA
05/2010
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
05/2010
1tyrosine receptor (receptor, tyrosine)IBA
12/2009
1Heat-Shock Proteins (Heat-Shock Protein)IBA
12/2009
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
06/2009
1LipidsIBA
06/2006
1Hormones (Hormone)IBA
06/2006

Therapy/Procedure

2Therapeutics
05/2010 - 06/2009